GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (STU:GBY) » Definitions » Issuance of Stock

Sangamo Therapeutics (STU:GBY) Issuance of Stock : €20.17 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Sangamo Therapeutics Issuance of Stock?

Sangamo Therapeutics's Issuance of Stock for the three months ended in Sep. 2024 was €0.00 Mil.

Sangamo Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was €20.17 Mil.


Sangamo Therapeutics Issuance of Stock Historical Data

The historical data trend for Sangamo Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Issuance of Stock Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.68 117.16 23.98 80.12 13.85

Sangamo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 20.72 -0.56 -

Sangamo Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €20.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sangamo Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics Business Description

Traded in Other Exchanges
Address
501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics Headlines

No Headlines